Myeloid‐derived suppressor cells and tumor: Current knowledge and future perspectives. Issue 7 (7th December 2018)

• Record Type: Journal Article
• Authors: Safari, Elahe; Ghorghanlu, Sajjad; Ahmadi‐khiavi, Homayoun; Mehranfar, Sahar; Rezaei, Ramazan; Motallebnezhad, Morteza
• Is Part Of: Journal of cellular physiology. Volume 234:Issue 7(2019:Jul.)
• Page Start: 9966
• Page End: 9981
• Publication Date: 2018-12-07
• Subjects: immunosuppression -- inflammation -- myeloid‐derived suppressor cells -- tumor; Physiology -- Periodicals; Cell physiology -- Periodicals; 571.6
• DOI: 10.1002/jcp.27923
• Languages: English
• ISSNs: 0021-9541

Abstract

Abstract: The immunosuppressive features of tumor lesions participate not only as one of the major players inducing cancer progression but also a big challenge for effective immunotherapy. It has been found that immunosuppression associated with chronic inflammatory factors, such as growth factors, cytokines, and chemokines is generated by stroma and tumor cells. Chronic and exhaustive secretion of these mediators triggers the generation of myeloid‐derived suppressor cells (MDSCs) demonstrating one of the key players engaged in tumor immunosuppression. In point of fact, direct cell‐to‐cell contact is a prerequisite for immunosuppressive functions of MDSCs. From the clinical perspective, the frequency of peripheral blood MDSCs is correlated with clinical stage and therapeutic response in various cancers. Furthermore, MDSCs are involved in chemoresistant settings. Altogether, it is a rational therapeutic approach to block the fierce cycle in which MDSCs are developed and infiltrated to favor cancer progression. In this review, we will summarize recent findings of MDSCs in tumor progression and discuss potential therapeutic strategies that could be evaluated in future clinical trials. Abstract : The manuscript discussed the weight of myeloid‐derived suppressor cells in tumor progression and therapeutic approaches to target these cells.